PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
BUSINESS
FDA Resumes Review of Capricor/Nippon Shinyaku’s DMD Cell Therapy
The US FDA has resumed its review of Capricor Therapeutics’ Duchenne muscular dystrophy (DMD) cell therapy deramiocel, also known as CAP-1002, the biotech said on March 10. The agency has set a new target action date of August 22. The…
To read the full story
Related Article
- FDA Extends Review of Capricor’s DMD Cell Therapy by 3 Months
August 26, 2026
- Nippon Shinyaku-Capricor DMD Therapy Dispute Heads to Arbitration
August 17, 2026
- Capricor Sues Nippon Shinyaku over US Rights to DMD Cell Therapy
May 11, 2026
- PIII Win for Capricor’s DMD Cell Therapy Sets Stage for New FDA Try
December 5, 2025
- FDA Rejects Capricor/Nippon Shinyaku’s DMD Cell Therapy, Seeking More Data
July 15, 2025
- DMD Cell Therapy Accepted for FDA Review: Capricor/Nippon Shinyaku
March 6, 2025
- Nippon Shinyaku Set to Expand Capricor DMD Therapy Pact to Europe
September 19, 2024
- Nippon Shinyaku Grabs Japan Rights to Capricor’s DMD Cell Therapy
February 17, 2023
- Nippon Shinyaku Snags US Commercial Rights to Capricor’s DMD Cell Therapy
January 26, 2022
BUSINESS
- Wholesalers See NHI-Market Price Gap Falling Below 4.8% to New Record Low
October 26, 2026
- Vyepti Could Expand Migraine Treatment Options: Japanese Expert
October 26, 2026
- Zeria to Buy German Asacol Manufacturing Partner
October 26, 2026
- Otsuka’s IgAN Drug Voyxact Cuts Kidney Event Risk by 97%
October 26, 2026
- NEC’s Neoantigen Therapy Shows Immunogenicity in Early TNBC Trial
October 26, 2026
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…